secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-09-18T21:00:57+00:00
Accession:  0001437749-26-030757
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech receives Nasdaq delisting notice; bid price below $1 for 30 days
--------------------------------------------------------------------------------

- Nasdaq notified Moleculin on Sept 15, 2026 that common stock failed minimum bid price ($1) from July 31 to Sept 11, 2026.
- Company ineligible for 180-day cure period due to 1-for-25 reverse stock split effected Dec 1, 2025.
- Company will request a hearing before Nasdaq Hearings Panel; trading continues pending panel decision.
- No assurance of continued listing; risk of suspension or delisting if hearing fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/0001437749-26-030757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/mbrx20260914_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-030757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer